Concept
Nilotinib
Publications associées (35)
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome-positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common "gatekeeper" mutation T315I ...
SPRINGER2021Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase
Florence Pojer, Sandrine Madeleine Suzanne Georgeon, Charlotte Julie Caroline Gehin, Oliver Hantschel, Sina Maren Reckel, Tim Kükenshöner, Delphine Maude Tardivon, Barbara Gerig, Sara Raquel Pereira Pinho
The two isoforms of the Bcr-Abl tyrosine kinase, p210 and p190, are associated with different leukemias and have a dramatically different signaling network, despite similar kinase activity. To provide a molecular rationale for these observations, we study ...
Springer Nature2017